Treatment with abiraterone significantly improves survival in advanced prostate cancer February 10, 2022 In December, researchers reported findings from a study showing that the drug abiraterone halves the risk of prostate cancer death among a specific group of patients who previously would not have been treated with it. Currently, abiraterone is approved only for men with prostate cancer that is spreading (metastasizing) in the body. But men enrolled in the study were treated at earlier stages, before their tumors had a chance to spread. Based on the findings, the investigators concluded that abiraterone should be considered for treating aggressive prostate cancer that has not yet begun to spread to other sites, but likely will in the future.Read the full article here.Source: Charlie Schmidt - Harvard Health Publications Prostate Cancer News
In December, researchers reported findings from a study showing that the drug abiraterone halves the risk of prostate cancer death among a specific group of patients who previously would not have been treated with it. Currently, abiraterone is approved only for men with prostate cancer that is spreading (metastasizing) in the body. But men enrolled in the study were treated at earlier stages, before their tumors had a chance to spread. Based on the findings, the investigators concluded that abiraterone should be considered for treating aggressive prostate cancer that has not yet begun to spread to other sites, but likely will in the future.Read the full article here.Source: Charlie Schmidt - Harvard Health Publications
